A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
about
Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndromeNew iPSC for old long QT syndrome modeling: putting the evidence into perspective.In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.KCNQ1 channels voltage dependence through a voltage-dependent binding of the S4-S5 linker to the pore domain.Generation of a Homozygous Transgenic Rat Strain Stably Expressing a Calcium Sensor Protein for Direct Examination of Calcium SignalingToward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT SyndromeIn silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.Pharmacogenetics of drug-induced arrhythmias.Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel.Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.Complex Brugada syndrome inheritance in a family harbouring compound SCN5A and CACNA1C mutations
P2860
Q24299159-6E53CF31-B789-4AEF-BCB2-B91401BF0568Q33163663-F3A82FEC-144F-46E3-8624-A928FB896BEDQ33791988-A8EA4759-100A-45DC-9385-D0741F6A7627Q34452725-62E2F9FF-34F5-4061-A44A-4248E96F10ABQ35909713-69DB7031-0F10-46FF-9C52-251C77A2E11EQ36141836-8D3B4FA6-5F77-4BFF-8128-471AE577BCA3Q37072877-AE8272FF-1A02-41EA-A4F2-869673B2C12CQ37960089-CF343927-43B8-4C82-9C56-F14253496485Q38177332-DE707FC6-BD31-4A99-A216-773959BCBA7CQ38671689-BF6C84E6-B86C-4B40-9A1E-B806997C8C49Q41819839-297A9A1D-C2AC-4A39-98B5-88BAD0A8C940Q42231933-F7DA60A0-0AC1-4FAC-82F7-0DF24E075CB0Q57406218-3EE8479B-6522-4071-A04C-D862E719F311
P2860
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@ast
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@en
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@nl
type
label
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@ast
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@en
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@nl
prefLabel
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@ast
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@en
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@nl
P2093
P50
P356
P1476
A common antitussive drug, clobutinol, precipitates the long QT syndrome 2
@en
P2093
Bénédicte Louérat-Oriou
Chloé Bellocq
Pierre Boisseau
Ronald Wilders
P304
P356
10.1124/MOL.104.001065
P407
P577
2004-11-01T00:00:00Z